Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novan Inc.

Betting nitric oxide therapeutics can succeed in skin

This article was originally published in Start Up

Executive Summary

Nitric oxide (NO) became a sudden celebrity in the early 1990s, as scientists recognized that the gas long known as a component of cigarette smoke and smog is also a vital chemical messenger within the body, but no one has yet been able to channel the academic understanding of NO into successful new medicines. Novan Inc. believes it can succeed where others have failed – the start-up aims first to create a topical treatment for acne, and then to pursue other first-in-class treatments in the field of dermatology.

You may also be interested in...



Novan Still Hopeful But May Be Stranded After Phase III Molluscum Failure

Nitric oxide-releasing SB206 missed the primary endpoint in a pair of Phase III studies, but Novan hopes a third study and success on a secondary endpoint still can lead to filing for approval.

Super-Specialist CROs: Commercializing Pharma R&D Expertise

Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.

Spero Therapeutics: Remodeling Antibiotics

Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.

Topics

Related Companies

UsernamePublicRestriction

Register

SC092456

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel